United States: Clinical Trials Part I: The Upcoming Clinical Trials Reporting Rule

In 2007, Congress passed the "Food and Drug Administration Amendments Act of 2007," the purpose of which was, in part, to update the FDA's rules surrounding clinical trials. The FDA took nearly a decade to review the law, seek public comment, and then daft a final Rule implementing its requirements. The "Final Rule for Clinical Trials Registration and Results Information Submission" was final on Sept. 21, 2016. This final Rule is intended to make it clear to industry members, investigators, and the public which trials must be reported to the federal government, how they are to be reported, when they must be reported and whether compliance with requirements has been achieved. The Rule will go into effect on Jan. 18, 2018 and will then be published in the Federal Register at 42 C.F.R. § 11.

ClinicalTrials.gov and historic practices

Since ClinicalTrials.gov was created, the U.S. Department of Health and Human Services has operated ClinicalTrials.gov as a single location to accomplish many tasks surrounding clinical trials. ClinicalTrials.gov is a vehicle by which patients can identify a study that they wish to participate in, as well as serving the purpose of openly tracking study progress and outcomes. This site:

  • Promotes research integrity by allowing simpler and more open changes to protocols and enabling greater research transparency;
  • Promoting evidence-based medicine, enhancing the ability for investigators to track and report outcomes and makes research easier to locate and evaluate;
  • Promotes more efficient allocation of resources by investigators because of its flexibility in creating and managing new trials.

By creating this site, the hope was that clinical trials were more open to the public both in terms of results, as well as identifying the studies that the FDA has indicated could move forward.  

Rule changes to reporting

However, even with the creation of ClinicalTrials.gov, follow-through by sponsors and investigators was not consistent. Often trial outcomes and registration of trials was not always performed, and utilization was not as high as the agency sought initially. As a result, the new Rule provides a legally enforced timeline for registration and results reporting, and study sponsors will be held responsible for compliance. Generally, the new Rule has several main provisions. The following is a simple summary of the Rule's requirements:

1. Requires registration and results submission for applicable clinical trials (also known as "ACTs").

a. ACTs are those trials that are:

i. Initiated on or after January 18, 2017 for studying an FDA-regulated drug or device; 

ii. Is for the purposes of performing studies which support an IND or IDE; 

iii. The facility is in the U.S., the product has been assigned an IND or IDE number, and even if the product will be manufactured in the US for export.

iv. Does not apply to Phase 1 clinical trials (for drugs or biologics) or trials for which the primary purpose is for device feasibility studies.

2. Clarifies and expands information required upon registration.

a. Registration information must be submitted no later than 21 calendar days after the first human subject is enrolled (known as the Study Start Date). 

b. Includes:

i. Information describing, in depth, the purpose and scope of the trial;

ii. Recruitment information, describing who will be considered for participation;

iii. Location information for the study; and

iv. Administrative data about the facility, the sponsor and other identifying information such as the Unique Protocol Identifier. 

c. Is submitted by the "Responsible Party" who is the sponsor as a default, and then is generally the principle investigator once one is designated.

3. Expands the scope of results reporting, including trials of unapproved products

a. Results reporting portal will be opened for testing around Oct. 22, 2017.

b. Final release of the online Protocol Registration and Results System ("PRS") will be in November 2017.

c. Results filing deadlines will be based on the trial's completion date. The new Rule applies to studies whose Primary Completion Date (date on which the final subject was examined or received an intervention for the purposes of final data collection) is on or after Jan. 18, 2017. Results reporting due one year after the primary completion date.

i. There are opportunities for extension, but no more than two years.

d. Results for studies involving products, whether or not they are approved, licensed or cleared by the FDA, must be reported if the trials were required to be registered.

4. Clarifies and expands the kinds of data that must be reported with results. Includes the following:

a. Participant "flow"

b. Demographic and baseline data

c. Outcomes and statistical analysis

d. Adverse event information

e. Protocol and statistical analysis plan

f. Administrative information like that provided during initial registration

5. Revises the Quality Control and ClinicalTrials.gov posting process.

These changes are potentially significant for investigators, sponsors or Contract Research Organizations (CROs) which have been in the clinical trial business for a significant period of time. These new requirements impose more structure on what was a poorly used system, which resulted in inconsistent use and follow-through. It is intended that under this new Rule, there will be a significant increase in the amount of data being provided to the FDA and potentially to the public. The new Rule is intended to expand the data that is accessible related to study outcomes. This expansion of data reporting and accessibility may pose some problems for companies in terms of protecting proprietary information for products not yet approved but are in the trial process. It will be critical that companies monitor their intellectual property protections and ensure that these protections are in place when reporting under the Rule.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions